2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome

The unique characteristics of patients with chronic coronary syndrome (CCS) in the Asia-Pacific region, heterogeneous approaches because of differences in accesses and resources and low number of patients from the Asia-Pacific region in pivotal studies, mean that international guidelines cannot be r...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jack Wei Chieh Tan, Derek P Chew, David Brieger, John Eikelboom, Gilles Montalescot, Junya Ako, Byeong-Keuk Kim, David KL Quek, Sarah J Aitken, Clara K Chow, Sok Chour, Hung Fat Tse, Upendra Kaul, Isman Firdaus, Takashi Kubo, Boon Wah Liew, Tze Tec Chong, Kenny YK Sin, Hung-I Yeh, Wacin Buddhari, Narathip Chunhamaneewat, Faisal Hasan, Keith AA Fox, Quang Ngoc Nguyen, Sidney TH Lo
Formato: article
Lenguaje:EN
Publicado: Radcliffe Medical Media 2021
Materias:
Acceso en línea:https://doaj.org/article/6e65974c60be45ae9133bd9a4386d9a8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The unique characteristics of patients with chronic coronary syndrome (CCS) in the Asia-Pacific region, heterogeneous approaches because of differences in accesses and resources and low number of patients from the Asia-Pacific region in pivotal studies, mean that international guidelines cannot be routinely applied to these populations. The Asian Pacific Society of Cardiology developed these consensus recommendations to summarise current evidence on the management of CCS and provide recommendations to assist clinicians treat patients from the region. The consensus recommendations were developed by an expert consensus panel who reviewed and appraised the available literature, with focus on data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting recommendations provide guidance on the assessment and management of bleeding and ischaemic risks in Asian CCS patients. Furthermore, the selection of long-term antithrombotic therapy is discussed, including the role of single antiplatelet therapy, dual antiplatelet therapy and dual pathway inhibition therapy.